The Blood and Marrow Transplant Clinical Trials Network conducted two parallel multicenter phase II trials for individuals with leukemia or lymphoma and no suitable related donor. Reduced intensity conditioning was used with either unrelated double umbilical cord blood (dUCB) or HLA-haploidentical related donor bone marrow (Haplo-marrow).
INTRODUCTION
Reduced intensity conditioning (RIC) has allowed older and less clinically fit patients with high risk hematologic malignancies to proceed to potentially curative treatment with allogeneic hematopoietic cell transplantation (HCT) [1] [2] [3] [4] [5] . For patients lacking an HLAmatched sibling, it is routine to initiate an unrelated donor search. However, a suitably matched unrelated donor cannot be identified for as many as one third of patients, even more for members of ethnic minorities. Even when an unrelated donor is identified, the interval between search initiation and transplantation can be as long as four months.
Consequently some patients, specially ethnic minorities, experience disease progression while awaiting identification of a suitably HLA-matched donor 6 Single center studies have shown that unrelated double umbilical cord blood (dUCB) 7, 8 and partially HLA-mismatched related bone marrow (Haplo-marrow) 9,10 are valuable alternative sources of donor cells for RIC HCT, thus extending this treatment modality to patients who lack a matched sibling or suitably matched unrelated donor. In order to study the reproducibility, and thus, the wider applicability of the two alternative donor strategies (dUCB and Haplo-marrow), The Blood and Marrow Transplantation Clinical Trials Network (BMT CTN) conducted two parallel phase II trials. Using identical inclusion and exclusion criteria and a common study design, these trials evaluated the efficacy of dUCB (BMT CTN 0604) and Haplo-marrow (BMT CTN 0603) after RIC regimens at 27 transplant centers in the United States. The goal of these studies was to generate pilot multicenter data to support a future phase III randomized clinical trial.
Patients and Methods
Eligible patients were ≤ 70 years of age with an advanced or high-risk leukemia or lymphoma and lacked a suitable matched related donor. Acute leukemia was required to be in morphological complete remission. Large cell, mantle cell and Hodgkin's lymphomas were required to have achieved at least a partial remission with treatment For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From prior to allogeneic transplantation. Low-grade lymphomas were required to have failed 2 prior chemotherapy regimens, but were not required to demonstrate chemotherapy sensitivity. A suitably matched related donor was defined as one matched or 1-locus mismatch at HLA-A, -B, -DRB1. A formal unrelated adult donor search was not a prerequisite for eligibility on either trial. Patients were required to have adequate organ function defined as: left ventricular ejection fraction > 35%; carbon monoxide corrected diffusion lung capacity (DLCO), forced expiratory volume in the first second (FEV 1 ) or functional vital capacity (FVC) > 50% of predicted; total bilirubin ≤ 2.5 mg/dl, and aspartate and alanine aminotransferases (ALT and AST), and alkaline phosphatase < 5
x upper limit of normal (ULN); serum creatinine within normal range for age, or measured creatinine clearance or calculated glomerular filtration rate > 40 mL/min/1.73m 2 . A Karnofsky performance score 60 to 100 was required, and patients who had undergone prior autologous transplantation were not excluded as long as 3 months had elapsed from the autologous transplant. Ten transplant centers enrolled patients only on the dUCB trial, 11 centers enrolled patients only on the Haplo-marrow trial and 6 centers enrolled on both trials. Centers that enrolled patients on both trials provided a document to the Data Coordinating Center that indicated patients/disease types they would enroll on each trial and the coordinating center ensured adherence. 
Graft and Donor Selection

Double unrelated donor cord blood (BMT CTN 0604)
In protocol 0604, all patients received two partially HLA-matched UCB units. The maximum allowable mismatch between the cord blood unit and the recipient, or between cord blood units, was two of six HLA loci (HLA-A, -B, at the antigen-level and -DRB1 at the allele-level). Each unit was required to contain a minimum pre-cryopreserved, nucleated cell dose of 1.5 x 10 7 per kilogram recipient weight. For UCB units that were not red cell depleted, the minimum cryopreserved nucleated cell dose was 2.0 x 10 7 per kilogram recipient body weight. Units were first selected for the best donor-recipient match and thereafter the total nucleated cell dose per kilogram of recipient body weight.
Anti-donor HLA antibody screen was not required for UCB unit selection. Units were thawed and infused per institutional practice after validation using methods reviewed and approved by the BMT CTN. The protocol recommended UCB unit thawing and processing as described by Rubinstein et al. 11 . After two patients had severe infusional reactions this method was required for all units containing more than 20 mL of erythrocytes. However, transplant centers were allowed to use a validated alternative processing technique.
HLA-haploidentical related donor bone marrow (BMT CTN 0603)
In protocol 0603, Haplo-marrow donors were required to be first-degree relatives of the patient defined as biological parents, siblings, children, or half-siblings. Donors and recipients were typed at HLA-A, -B, -C, -DRB1 and -DQB1 at the allele level. Donorrecipient pairs were considered HLA-haploidentical if they were genotypically identical for at least one allele of each of these loci. Donors were required to be ≥ 18 years of age and screened per the American Association of Blood Banks (AABB) guidelines.
Donors were excluded if the recipient's serum contained anti-donor HLA antibodies. In For personal use only. on November 12, 2017. by guest www.bloodjournal.org From the event that two or more eligible donors were identified, donor selection hierarchy was: first, donor-recipient matching of CMV serology and second, donor-recipient red blood cell compatibility. An earlier report did not show a detrimental effect of increasing donorrecipient HLA-mismatch on outcomes after non-myeloablative HLA-haploidentical BMT with post-transplantation cyclophosphamide. 12 Therefore, the number of mismatched HLA alleles between donor and recipient was not considered as a criterion for donor selection.
Conditioning Regimens and Immunosuppressive Therapies
Double unrelated donor cord blood (BMT CTN 0604)
Recipients of cord blood grafts were conditioned with fludarabine (Flu) 40 mg/m 2 /day intravenously (IV) from days -6 to -2 (total dose of 200 mg/m 2 ), cyclophosphamide (Cy) 50mg/kg IV on day -6, and 2 Gy total body irradiation (TBI) in a single fraction on day -1 ( Figure 1A) . The dose of fludarabine was adjusted for creatinine clearance as clinically prophylaxis included mycophenolate mofetil (MMF) given at 1 gram every 8 hours for patients > 50 kg of body weight or 15 mg/kg every 8 hours for those < 50 kg beginning on day -3 and continued until day +30 or 7 days after engraftment, whichever was later.
In addition, patients received cyclosporine A to achieve a target trough level of 200-400 ng/mL until day +100; in the absence of GVHD, taper was instituted at 10% of dose per week beginning on day +101 and discontinued approximately day +180-200. Tacrolimus dosed to achieve a target trough level of 5-10 ng/mL could be substituted for cyclosporine. Filgrastim was initiated on day +1 at 5 mcg/kg/day and continued until the absolute neutrophil count (ANC) was ≥ 2,000/mcL for 3 consecutive days.
HLA-haploidentical related donor bone marrow (BMT CTN 0603)
Recipients of HLA-haploidentical related donor grafts were conditioned with Flu 30 mg/m 2 /day IV daily from days -6 to -2 (total dose of 150 mg/m 2 ), Cy 14.5 mg/kg IV on day -6 and -5, and 2 Gy TBI in a single fraction on day -1 (Figure 1B) . The dose of fludarabine was adjusted for creatinine clearance as clinically indicated. For patients with actual body weight > 125% of ideal body weight (IBW), Cy was dosed based on AIBW as above with mesna and vigorous IV hydration for uroprotection. GVHD prophylaxis consisted of Cy 50 mg/kg IBW by IV infusion over 1-2 hours on days +3
(between 60 and 72 hours after marrow infusion) and +4 after transplantation. In addition, patients received tacrolimus and MMF that were initiated on day +5 after transplantation. MMF was given at a dose of 15 mg/kg every 8 hours with the maximum total daily dose not to exceed 3 grams. MMF prophylaxis was discontinued on day +35 or continued at the discretion of the treating center if active GVHD was present.
Tacrolimus was dosed to achieve a target trough level of 5-10 ng/mL with the goal of discontinuing by day +180 after transplantation. Filgrastim was initiated on posttransplantation day +5 at a dose of 5 mcg/kg/day and continued until the ANC was ≥ 1000/mcL for three consecutive days.
Supportive Care
Supportive care, including blood product administration, prophylaxis and therapy of infection, and treatment of GVHD, was at the discretion of treating physicians and transplant center practices.
Statistical Considerations
The primary endpoint of both trials was overall survival (OS) at 180 days after transplantation, based on the hypothesis that the probability of OS would not be inferior For personal use only. on November 12, 2017. by guest www.bloodjournal.org From to that reported after RIC adult unrelated donor transplantation (60% at day +180) 1 . The target sample size of 50 on each trial would provide 84% power to reject the null hypothesis if the true OS is <40%. Non-relapse mortality (NRM) and graft failure were monitored monthly against pre-specified safety boundaries with the sequential probability ratio test and no boundaries for safety endpoints were triggered during the trial. Secondary endpoints included progression-free survival (PFS) and cumulative incidences of hematopoietic recovery, grades II-IV and III-IV acute GVHD, chronic GVHD, relapse, and NRM. Time to neutrophil recovery was defined as the interval between transplantation and the first of the three consecutive neutrophil counts ≥ 500/mcL. Time to platelet recovery was defined as the interval between transplantation and the first of three consecutive measurements of a platelet count >20,000/ mcL or >50,000/ mcL without a platelet transfusion in the preceding seven days. Donor cell engraftment was defined as >5% donor chimerism on day +56 or beyond after transplantation, and graft failure was defined as <5% donor chimerism. Patients who did not achieve neutrophil recovery and died within 28 days after transplantation were also scored as graft failures. Chimerism was evaluated at days +28, +56, +180 and +365 post-transplantation in whole blood or marrow and/or T cells according to institutional practice by either variable nucleotide tandem repeats or single tandem repeats. For the purpose of the dUCB study the chimerism of both donor units was combined.
The probabilities of OS and PFS were calculated using the Kaplan-Meier estimator. 12 For OS, death from any cause was considered an event and for PFS, the first occurrence of relapse post-transplant, disease progression or death was considered an event. Patients without an event were censored at last follow-up. Neutrophil and platelet recovery were calculated using the cumulative incidence function 12 with death prior to recovery as the competing risk. The incidence of acute GVHD and chronic GVHD were calculated using the cumulative incidence function, with death, relapse or For personal use only. on November 12, 2017. by guest www.bloodjournal.org From disease progression, and graft failure as competing risks. The incidence of NRM and relapse was calculated using the cumulative incidence function; for NRM, relapse was the competing risk and for relapse or disease progression, NRM was the competing risk.
All analyses were done using SAS software version 9.2 (Carey, NC).
RESULTS
Patient, donor, and graft characteristics
Characteristics of the patients in the two clinical trials are summarized in Table 1 , and of the donors and grafts in Table 2 . Table 2) .
Hematopoietic Recovery and Chimerism
After dUCB transplantation, the cumulative incidence of neutrophil recovery >500/mcL at day +56 was 94% (95%CI, 87-100%) with a median time to recovery of 15 days (range, 4-47) (Figure 2A) . The cumulative incidence of platelet recovery, ≥ 20,000/mcL at day +100 was 82% (95%CI, 71-93%) with a median time to recovery of 38 days (range, 3-87). Corresponding probability for platelets ≥ 50,000/mcL was 59% (95%CI, 44-73%) with a median time to recovery of 43 days (range, 29-323) (Figure 2B ). There were five cases of primary graft failure and one secondary graft failure. Three graft failure patients died at days +23, +28 and +193 (after second dUCB transplant). Two patients had autologous reconstitution and died of relapse at day +99 and +117. The patient with secondary graft failure was determined to have lost chimerism at day +183, had leukemia relapse at day +330 and died at day +347. Median donor chimerism in marrow or peripheral blood was 92% (range, 0-100%) on day +28 and 100% (range, 25-100%) on day +56 after transplantation. The two patients with autologous reconstitution who relapsed prior to day +56 were excluded for chimerism reporting at day +56. Six patients had mixed chimerism at day+56; four of these patients were 100% donor at day+180. The remaining two patients died, one from recurrent disease and the other from acute GVHD before day+180 chimerism assay.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From After Haplo-marrow the cumulative incidence of neutrophil recovery >500/mcL at day +56 was 96% (95%CI, 90-100%) with a median time to recovery of 16 days (range, 12-83) (Figure 2D) . The cumulative incidence of platelet recovery ≥ 20,000/mcL at day +100 was 98% (95%CI, 93-100%) with a median time to recovery of 24 days (range, 1-92). The corresponding probability for platelets ≥ 50,000/mcL was 76% (95%CI, 64-88%) with a median time to recovery of 26 days (range, 1-126) (Figure 2E ). There was one case of primary graft failure. This patient did not receive a second transplant and died at day +67. Median donor chimerism in marrow or peripheral blood was 100% (range 72-100%) on day +28 and 100% (range 0-100%) on day +56 after transplantation. All patients had 100% donor chimerism at day+56.
Toxicities
Targeted grade 3 to 5 toxicities were reported on 56% and 30% of patients after dUCB and Haplo-marrow transplantation, respectively. The frequency of targeted toxicities observed by day +180 post-transplantation by organ system and grade attribution and number of patients experiencing toxicities are summarized in Table 3 ; there were no grade 5 toxicities reported in either trial between days 0 and +180. In the dUCB recipients, grade 3 to 5 infusion related toxicities included hypertension (n=5), dyspnea/hypoxia (n=3), allergic/chills (n=2), nausea/vomiting (n=2), arrhythmia (n=1) and hypotension (n=1). No grade 3 to 5 toxicities were reported within 24h of Haplomarrow infusion.
Graft-versus-host disease
After dUCB transplantation, the cumulative incidences of grade II-IV and III-IV acute GVHD at day +100 were 40% (95% CI, 26-54%) and 21% (95% CI, 6-37%), respectively ( Figure 3A) . The cumulative incidence of chronic GVHD at 1 year was 25% (95% CI, 12-39%) (Figure 3B) .
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From After Haplo-marrow, the cumulative incidence of grade II-IV acute GVHD at day +100 was 32% (95% CI, 19-45%) (Figure 3C ). There were no reported cases of grade III-IV acute GVHD. The cumulative incidence of chronic GVHD at 1 year was 13% (95% CI, 3-23%) (Figure 3D) .
Non-Relapse Mortality, Relapse, and Survival
After dUCB transplantation, the median follow-up of surviving patients was 365 days (range, 56-411 days). The 1-year cumulative incidence of NRM was 24% (95% CI, 11-36%) and relapse/progression, 31% (95% CI, 17-44%) (Figure 4A) . The most frequent cause of death was relapse ( Table 4 ). Six-month survival, which was the primary endpoint, was 74% (95%CI, 59-84%). The 1-year probability of progression-free survival was 46% (95% CI, 31-60%) and overall survival 54% (95% CI, 38-67%) (Figure 4B) .
After Haplo-marrow, the median follow-up of surviving patients was 357 days (range 103-441). The 1-year cumulative incidence of NRM was 7% (95% CI, 0-15%) and relapse/progression was 45% (95% CI, 30-61%) (Figure 4C) . The most frequent cause of death was also relapse ( Table 4 ). Six-month survival, which was the primary endpoint, was 84% (95%CI, 70-92%). The 1-year probability of progression-free survival was 48% (95% CI, 32-62%) and overall survival 62% (95% CI, 44-76%) (Figure 4D) .
DISCUSSION
Our approach of running parallel multi-center phase II trials with identical objectives, eligibility criteria, and clinical endpoints achieved the important strategic objective of reproducing the encouraging single center results with dUCB and Haplo-marrow transplantation as previously reported 8, 10 . Centers were not required to participate in both trials and patients were not randomly assigned to one versus the other trial; thus, the outcomes were not and should not be compared directly. However, our data suggest that survival rates after RIC and either dUCB or Haplo-marrow transplantation For personal use only. on November 12, 2017. by guest www.bloodjournal.org From are comparable to survival rates in patients with high-risk hematologic malignancies who were transplanted with blood or marrow from matched unrelated donors after RIC in a registry based study 1 .
RIC increases the number of potential candidates for allogeneic BMT by increasing the number of patients expected to tolerate the procedure. For the many patients without available related donors, most transplant centers have established algorithms for utilization of alternative donor sources, with the choice of the alternative donor largely influenced by institutional expertise and research priorities. While several transplant centers search the unrelated donor registries simultaneously for adult donors and UCB, others favor related HLA-haploidentical donors.
The prospective trials described here sought to determine whether the promising single or two center outcomes 8,10 could be reproduced in multicenter, cooperative group settings. Although accrual of 50 patients to each trial was estimated to require three years, both trials met their accrual goals in about half that time. The rapid patient accrual can be attributed to the great interest in better understanding the effectiveness of these alternative donor sources in order to close the gap in donor availability.
The dUCB strategy has been widely used to overcome the cell dose limitation of a single UCB unit for adults and larger adolescents. The outcomes observed in this trial were consistent with those reported from a single center and registry data showing promising outcomes after RIC dUCB transplantation 7, 8, 13 . While data on the outcomes of patients undergoing a RIC UCB comparing 1 vs. 2 UCB units graft are limited 8, 13 , single UCB transplantation is feasible if the total nucleated cell dose of the unit is deemed acceptable [14] [15] [16] [17] . However, large numbers of adults cannot find a single unit 8 with the required minimum cryopreserved cell dose of 2.5-3.0 x10 7 /kg 18 . Thus, in order to keep the treatment homogeneous, we chose to use dUCB grafts for all patients.
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The primary limitation to Haplo-marrow has been intense bi-directional alloreactivity resulting in high incidences of graft failure and severe GVHD. High dose, post-transplantation Cy was initially developed in animal models as a method for inducing tolerance to histocompatibility antigens, and was found to mitigate both graft rejection and GVHD after major histocompatibility complex-mismatched BMT 19 . An initial concern was that high dose post-transplantation Cy might be toxic to donor stem cells, significantly delaying hematopoietic recovery. However, lympho-hematopoietic stem cells are relatively quiescent and express high levels of aldehyde dehydrogenase, which likely confers cellular resistance to cyclophosphamide 20 . Indeed, the kinetics of donor neutrophil and platelet recovery were acceptable in the initial phase I/II trials 9, 10 .
The limited numbers of patients enrolled per center prevented us from examining for a transplant center effect on survival. Nevertheless, these parallel multi-center phase II trials achieved the two important goals of reproducing results reported at single institutions in the multicenter setting and provided preliminary data that suggest outcomes achieved with dUCB and Haplo-marrow transplantation with RIC regimens are comparable to those reported after matched unrelated donors transplantation. 1 Taken together, these results set the stage for a multicenter, randomized phase III trial to evaluate the relative risks and benefits of dUCB versus Haplo-marrow with RIC regimens.
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